- Oops!Something went wrong.Please try again later.
Jardiance aced the primary endpoint in a pivotal outcomes trial in heart failure patients with a preserved ejection fraction (HFpEF) with or without Type 2 diabetes.
Jardiance cut the composite risk of cardiovascular (CV) death or hospitalization by 25% compared with placebo, potentially adding to the drug’s current label to improve glycemic control and lower the risk of CV death in patients with Type 2 diabetes and established CV disease.
Meanwhile, the FDA is currently reviewing the drug to treat heart failure patients with a reduced ejection fraction (HFrEF) with or without Type 2 diabetes based on the EMPEROR-REDUCED Phase 3 study results.
The companies expect to present full data from the Phase 3 EMPEROR-PRESERVED study at the European Society of Cardiology annual meeting in August and plan to file for regulatory submission by the 2021 end.
Price Action: LLY shares are down 0.13% at $234.28 during the market session on the last check Tuesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.